Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden

Nguyen LH, Örtqvist AK, Cao Y, Simon TG, Roelstraete B, Song M, Joshi AD, Staller K, Chan AT, Khalili H, Olén O, Ludvigsson JF, Published November, 2020 in the Lancet Gastroenterology & Hepatology

Systematic Review on Inflammatory Bowel Disease Patients with Coronavirus Disease 2019: It Is Time to Take Stock

D'Amico F, Danese S, Peyrin-Biroulet L, Published November, 2020 in the Clinical Gastroenterology and Hepatology

Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial

Chaparro M, Gordillo J, Domènech E, Esteve M, Barreiro-de Acosta M, Villoria A, Iglesias-Flores E, Blasi M, Naves JE, Benítez O, Nieto L, Calvet X, García-Sánchez V, Villagrasa JR, Marin AC, Donday MG, Abad-Santos F, Gisbert JP,  Published November, 2020 in the American Journal of Gastroenterology

Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID

Chapuis-Biron C, Kirchgesner J, Pariente B, Bouhnik Y, Amiot A, Viennot S, Serrero M, Fumery M, Allez M, Siproudhis L, Buisson A, Pineton de Chambrun G, Abitbol V, Nancey S, Caillo L, Plastaras L, Savoye G, Chanteloup E, Simon M, Dib N, Rajca S, Amil M, Parmentier AL, Peyrin-Biroulet L, Vuitton L; GETAID BioLAP Study Group, Published November, 2020 in the American Journal of Gastroenterology

Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel

Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F, Cooney R, Dart RJ, Galloway J, Gaya DR, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees CW, Limdi JK, Lindsay JO, Patel K, Powell N, Murray CD, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan MA, Irving PM, Published October, 2020 in the Gut

Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn’s Disease

Xiaojun Zhuang, MD, Zhenyi Tian, MD, Rui Feng, MD, Manying Li, MD, Tong Li, MD, Gaoshi Zhou, MD, Yun Qiu, MD, Baili Chen, MD, Yao He, MD, Minhu Chen, MD, Zhirong Zeng, MD, Shenghong Zhang, MD, Published November, 2020 in the Inflammatory Bowel Diseases Journal

Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn’s Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial

Manar Matar, MD, Raanan Shamir, MD, Dan Turner, MD, Efrat Broide, MD, Batia Weiss, MD, Oren Ledder, MD, Anat Guz-Mark, MD, Firas Rinawi, MD, Shlomi Cohen, MD, Chani Topf-Olivestone, MD, Ron Shaoul, MD, Baruch Yerushalmi, MD, Shomron Ben-Horin, MD, Amit Assa, MD, Published November, 2020 in the Inflammatory Bowel Diseases Journa

Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure

Flanagan E, Gibson PR, Wright EK, Moore GT, Sparrow MP, Connell W, Kamm MA, Begun J, Christensen B, De Cruz P, Shelton E, Dowling D, Andrews JM, Brown SJ, Niewiadomski O, Ward MG, Rosella O, Rosella G, Kiburg KV, Ross AL, Bell SJ; PICCOLO Study Group, Published November, 2020 in the Alimentary Pharmacology & Therapeutics

Pre‐treatment magnetic resonance enterography findings predict the response to TNF‐alpha inhibitors in Crohn's disease

Rimola J, Fernàndez-Clotet A, Capozzi N, Rojas-Farreras S, Alfaro I, Rodríguez S, Masamunt MC, Ricart E, Ordás I, Panés J. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease, Published September, 2020 in the Alimentary Pharmacology & Therapeutics